Seres Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Seres Therapeutics, Inc. (Nasdaq: MCRB) on October 4, 2023, covering an event that occurred on October 2, 2023. The filing addresses a change in the Company's board of directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to corporate governance updates and does not contain financial performance data.
Material Changes
On October 2, 2023, Grégory Behar resigned from the board of directors of Seres Therapeutics, Inc., effective immediately. This resignation is in connection with his departure from Nestlé Health Science.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the specific event of the director's departure.
Key Facts for Investor Verification
- Grégory Behar has resigned from the Seres Therapeutics board of directors.
- The resignation became effective immediately on October 2, 2023.
- The departure is linked to Mr. Behar's resignation from Nestlé Health Science.
- Thomas J. DesRosier, Chief Legal Officer and Executive Vice President, signed the report on behalf of the Company.